Nutrition and age-related macular degeneration: Research evidence in practice

Optometry and Vision Science

Volumn 91, Issue 8, 2014, Pages 821-831

  Downie, Laura Elizabeth ^a,b   Keller, Peter Richard ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

Author keywords

Age related macular degeneration; Antioxidant; AREDS; Diet; Drusen; Mineral; Nutrition; Nutritional supplements; Vitamin; Zinc

Indexed keywords

ANTIOXIDANTS; MINERALS; OPHTHALMOLOGY; VITAMINS; ZINC;

AGE-RELATED; AGE-RELATED MACULAR DEGENERATION; AREDS; CLINICAL STUDY; DEVELOPED COUNTRIES; DRUSEN; NUTRITIONAL SUPPLEMENTS; VISUAL IMPAIRMENT;

NUTRITION;

OMEGA 3 FATTY ACID; VITAMIN; XANTHOPHYLL;

DIET SUPPLEMENTATION; DISEASE COURSE; HUMAN; MEDICAL RESEARCH; NUTRITION; PATHOPHYSIOLOGY; RETINA MACULA DEGENERATION; REVIEW; RISK FACTOR;

BIOMEDICAL RESEARCH; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; FATTY ACIDS, OMEGA-3; HUMANS; MACULAR DEGENERATION; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; RISK FACTORS; VITAMINS; XANTHOPHYLLS;

EID: 84904969163     PISSN: 10405488     EISSN: 15389235     Source Type: Journal    
DOI: 10.1097/OPX.0000000000000285     Document Type: Review

References (75)

1. CongdonN, O'ColmainB, KlaverCC, KleinR, Munoz B, FriedmanDS, Kempen J, Taylor HR, Mitchell P, Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004; 122: 477-85.
2. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J, Eye Diseases Prevalence Research G. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122: 564-72.
3. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye (Lond) 2005; 19: 935-44.
4. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000; 45: 115-34.
5. Feeney L, Berman ER. Oxygen toxicity: membrane damage by free radicals. Invest Ophthalmol 1976; 15: 789-92.
6. Hayes KC. Retinal degeneration in monkeys induced by deficiencies of vitamin E or A. Invest Ophthalmol 1974; 13: 499-510.
7. Young RW. Solar radiation and age-related macular degeneration. Surv Ophthalmol 1988; 32: 252-69.
8. Buring JF, Hennekens CH. Antioxidant vitamins in cancer: the Physicians' Health Study and Women's Health Study. In: Prasad KN, Santamaria L, Williams RM, eds. Nutrients in Cancer Prevention and Treatment (Experimental Biology and Medicine: Book 27). Totowa, NJ: Humana; 1995: 223-34.
9. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328: 1444-9.
10. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-35.
11. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-5.
12. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119: 1417-36.
13. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013; 309: 2005-15.
14. Bird AC, Bressler NM, Bressler SB, Chisholm IH, CoscasG, Davis MD, de Jong PT, Klaver CC, Klein BE, Klein R, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995; 39: 367-74.
15. Seddon JM, Sharma S, Adelman RA. Evaluation of the clinical agerelatedmaculopathy staging system.Ophthalmology 2006; 113: 260-6.
16. Davis MD, Gangnon RE, Lee LY, Hubbard LD, Klein BE, Klein R, Ferris FL, Bressler SB, Milton RC. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol 2005; 123: 1484-98.
17. Ferris FL, 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, Sadda SR. Clinical classification of age-related macular degeneration. Ophthalmology 2013; 120: 844-51.
18. Downie LE, Hodgson LA, Dsylva C, McIntosh RL, Rogers SL, Connell P, Wong TY. Hypertensive retinopathy: comparing the Keith-Wagener-Barker to a simplified classification. J Hypertens 2013; 31: 960-5.
19. DietaryGuidelines.gov. Dietary Guidelines for Americans. Available at: http: //www.health.gov/dietaryguidelines/Default.asp. Accessed September 1, 2013.
20. U.S. Food and Drug Administration (FDA). Q&A on Dietary Supplements. Available at http: //www.fda.gov/Food/DietarySupplements/QADietarySupplements/ default.htm. Accessed September 20, 2013.
21. Harvey B. AREDS2: what does it mean in practice? Optician 24.05.13. Available at: http: //www.opticianonline.net/assets/getAsset.aspx?Item ID=6900. Accessed April 16, 2014.
22. Rosenthal JM, Kim J, de Monasterio F, Thompson DJ, Bone RA, Landrum JT, de Moura FF, Khachik F, Chen H, Schleicher RL, Ferris FL, 3rd, Chew EY. Dose-ranging study of lutein supplementation in persons aged 60 years or older. Invest Ophthalmol Vis Sci 2006; 47: 5227-33.
23. Huang LL, Coleman HR, Kim J, de Monasterio F, Wong WT, Schleicher RL, Ferris FL, 3rd, Chew EY. Oral supplementation of lutein/zeaxanthin and omega-3 long chain polyunsaturated fatty acids in persons aged 60 years or older, with or without AMD. Invest Ophthalmol Vis Sci 2008; 49: 3864-9.
24. Blackmores. Fish Oil 1000. Available at: http: //www.blackmores. com.au/products/fish-oil-1000. Accessed September 20, 2013.
25. Jüni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001; 323: 42-6.
26. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c332.
27. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials. A survey of three medical journals. N Engl J Med 1987; 317: 426-32.
28. Musch DC. Evidence for including lutein and zeaxanthin in oral supplements for age-related macular degeneration. JAMA Ophthalmol 2014; 132: 139-41.
29. Downie LE, Keller PR. Making sense of the evidence: the Age- Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial. JAMA Ophthalmol 2014: in press.
30. Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database Syst Rev 2012; 6: CD000253.
31. Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev 2012; 11: CD000254.
32. Garrett SK, McNeil JJ, Silagy C, Sinclair M, Thomas AP, Robman LP, McCarty CA, Tikellis G, Taylor HR. Methodology of the VECAT study: vitamin E intervention in cataract and age-related maculopathy. Ophthalmic Epidemiol 1999; 6: 195-208.
33. Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K, Tsipursky M, Nyland J. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 2004; 75: 216-30.
34. Richer S, Devenport J, Lang JC. LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry 2007; 78: 213-9.
35. Piermarocchi S, Saviano S, Parisi V, Tedeschi M, Panozzo G, Scarpa G, Boschi G, Lo Giudice G, Carmis Study Group. Carotenoids in Age- Related Maculopathy Italian Study (CARMIS): two-year results of a randomized study. Eur J Ophthalmol 2012; 22: 216-25.
36. Richer S. Multicenter ophthalmic and nutritional age-related macular degeneration studyVpart 2: antioxidant intervention and conclusions. J Am Optom Assoc 1996; 67: 30-49.
37. Bartlett HE, Eperjesi F. Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial. Eur J Clin Nutr 2007; 61: 1121-7.
38. Awh CC, Lane AM, Hawken S, Zanke B, Kim IK. CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology 2013; 120: 2317-23.
39. Seddon JM, Ajani UA, Sperduto RD, Hiller R, Blair N, Burton TC, Farber MD, Gragoudas ES, Haller J, Miller DT, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA 1994; 272: 1413-20.
40. Augood C, Chakravarthy U, Young I, Vioque J, de Jong PT, Bentham G, RahuM, Seland J, Soubrane G, Tomazzoli L, Topouzis F, Vingerling JR, et al. Oily fish consumption, dietary docosahexaenoic acid and eicosapentaenoic acid intakes, and associations with neovascular age-related macular degeneration. Am J Clin Nutr 2008; 88: 398-406.
41. Sangiovanni JP, Agron E, Meleth AD, Reed GF, Sperduto RD, Clemons TE, Chew EY, Age-Related Eye Disease Study Research G. {omega}-3 Long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: AREDS report 30, a prospective cohort study from the Age-Related Eye Disease Study. Am J ClinNutr 2009; 90: 1601-7.
42. Chew EY, SanGiovanni JP. Lutein. In: Coates PM, Blackman MR, Cragg GM, Levine M, Moss J, White JD, eds. Encyclopedia of Dietary Supplements. New York, NY: Marcel Dekker; 2005: 409-20.
43. Chew E, Age-Related Eye Disease 2 Study Group. Age-Related Eye Disease Study 2 Protocol, 23 September 2009. Available at: https://web.emmes.com/study/ areds2/resources/areds2-protocol.pdf. Accessed April 16, 2014.
44. Fliesler SJ, Anderson RE. Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res 1983; 22: 79-131.
45. Litman BJ, Mitchell DC. A role for phospholipid polyunsaturation in modulating membrane protein function. Lipids 1996; 31 (Suppl.): S193-7.
46. Hoffman DR, Birch DG. Docosahexaenoic acid in red blood cells of patients with X-linked retinitis pigmentosa. Invest Ophthalmol Vis Sci 1995; 36: 1009-18.
47. Dreyer C, Keller H, Mahfoudi A, Laudet V, Krey G, Wahli W. Positive regulation of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Biol Cell 1993; 77: 67-76.
48. Rotstein NP, Aveldano MI, Barrantes FJ, Roccamo AM, Politi LE. Apoptosis of retinal photoreceptors during development in vitro: protective effect of docosahexaenoic acid. J Neurochem 1997; 69: 504-13.
49. Chew EY, Clemons T, SanGiovanni JP, Danis R, Domalpally A, McBeeW, Sperduto R, Ferris FL. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology 2012; 119: 2282-9.
50. Kaiser HJ, Flammer J, Stumpfig D, Hendrickson P. Visaline in the treatment of age-related macular degeneration: a pilot study. Ophthalmologica 1995; 209: 302-5.
51. Ma L, Dou HL, Huang YM, Lu XR, Xu XR, Qian F, Zou ZY, Pang HL, Dong PC, Xiao X, Wang X, Sun TT, et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebocontrolled trial. Am J Ophthalmol 2012; 154: 625-34.
52. Luu CD, Dimitrov PN, Wu Z, Ayton LN, Makeyeva G, Aung KZ, Varsamidis M, Robman L, Vingrys AJ, Guymer RH. Static and flicker perimetry in age-related macular degeneration. Invest Ophthalmol Vis Sci 2013; 54: 3560-8.
53. Wu Z, Ayton LN, Guymer RH, Luu CD. Intrasession test-retest variability of microperimetry in age-related macular degeneration. Invest Ophthalmol Vis Sci 2013; 54: 7378-85.
54. Downie LE, Cheng AS, Vingrys AJ. Color vision deficits in intermediate age-related macular degeneration. Optom Vis Sci 2014; 91: 932-8.
55. Gin TJ, Luu CD, Guymer RH. Central retinal function as measured by the multifocal electroretinogram and flicker perimetry in early age-related macular degeneration. Invest Ophthalmol Vis Sci 2011; 52: 9267-74.
56. Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996; 312: 71-2.
57. Collins K. Innisfil Eye Care: Can Healthful Eating Save Your Eyes? http: //www.innisfileyecare.com/view/article-72.3conx. Accessed September 6, 2013.
58. Valavanidis A, Vlachogianni T, Fiotakis K. Tobacco smoke: involvement of reactive oxygen species and stable free radicals in mechanisms of oxidative damage, carcinogenesis and synergistic effects with other respirable particles. Int J Environ Res Public Health 2009; 6: 445-62.
59. Tomany SC, Wang JJ, Van Leeuwen R, Klein R, Mitchell P, Vingerling JR, Klein BE, Smith W, De Jong PT. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 2004; 111: 1280-7.
60. Leffondre K, Abrahamowicz M, Siemiatycki J, Rachet B. Modeling smoking history: a comparison of different approaches. Am J Epidemiol 2002; 156: 813-23.
61. U.S. Preventive Services Task Force (USPSTF). Guide to Clinical Preventive Services, 1st ed. Washington, DC: Office of Disease Prevention and Health Promotion; 1989.
62. Lawrenson JG, Evans JR. Advice about diet and smoking for people with or at risk of age-related macular degeneration: a cross-sectional survey of eye care professionals in the UK. BMC Public Health 2013; 13: 564.
63. Mares-Perlman JA, Fisher AI, Klein R, Palta M, Block G, Millen AE, Wright JD. Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. Am J Epidemiol 2001; 153: 424-32.
64. van Leeuwen R, Boekhoorn S, Vingerling JR, Witteman JC, Klaver CC, Hofman A, de Jong PT. Dietary intake of antioxidants and risk of agerelated macular degeneration. JAMA 2005; 294: 3101-7.
65. RoyalCollege ofOphthalmologists.Age-RelatedMacularDegenerationV Guidelines for ManagementVUpdate; 2009. Available at: http: //www. rcophth.ac.uk/page.asp?section=451§ionTitle=Clinical+Guidelines. Accessed April 10, 2014.
66. College of Optometrists. Healthy lifestyle, healthy eyes. Available at: http: //lookafteryoureyes.org/eye-care/healthy-lifestyle-healthy-eyes/. Accessed September 7, 2013.
67. Thomson CD, Chisholm A, McLachlan SK, Campbell JM. Brazil nuts: an effective way to improve selenium status. Am J Clin Nutr 2008; 87: 379-84.
68. Evans JR, Fletcher AE, Wormald RP. 28, 000 Cases of age related macular degeneration causing visual loss in people aged 75 years and above in the United Kingdom may be attributable to smoking. Br J Ophthalmol 2005; 89: 550-3.
69. Khan JC, Thurlby DA, Shahid H, Clayton DG, Yates JR, Bradley M, Moore AT, Bird AC. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 2006; 90: 75-80.
70. Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. Control Clin Trials 1999; 20: 573-600.
71. Druesne-Pecollo N, Latino-Martel P, Norat T, Barrandon E, Bertrais S, Galan P, Hercberg S. Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials. Int J Cancer 2010; 127: 172-84.
72. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev 2008: CD000165.
73. Chew EY, Clemons T. Vitamin E and the age-related eye disease study supplementation for age-related macular degeneration. Arch Ophthalmol 2005; 123: 395-6.
74. Australian Macular Degeneration Foundation. AREDS2 results. Available at: http: //www.mdfoundation.com.au/page1220371.aspx. Accessed September 8, 2013.
75. Ocular Nutrition Society. Position statement on AREDS2. Available at: http: //www.ocularnutritionsociety.org/position-statement-on-areds2. Accessed September 8, 2013.